Having a mutation in BRCA1 can increase a person’s risk of developing breast cancer. LYN kinase is switched on in cells where BRCA1 is mutated. Professor Smalley will investigate whether this protein could be targeted to treat and prevent breast cancer.

Dr Nora Pashayan would like to find the best way to personalise the breast screening programme, adjusting screening timing and frequency according to a woman’s individual risk, in order to maximise the benefits and minimise the potential harms of screening.

We know that our genetics play a key role in determining breast cancer risk, but we need to know much more about the specific genes involved and how they affect an individual person’s risk.